Demographic characteristics and prevalence of comorbidities of allopurinol episodes with atrial fibrillation
| Episodes with atrial fibrillation | ||||
|---|---|---|---|---|
| No atrial fibrillation NE=7878 | Not on allopurinol NE=565 | On allopurinol NE=801 | p Value | |
| Age, mean (SD) | 78.2 (7.2) | 78.0 (7.3) | 78.4 (7.1) | 0.42 |
| Gender, N (%) | 0.65 | |||
| Male | 3430 (43.5) | 240 (42.5) | 350 (43.7) | |
| Female | 4448 (56.5) | 325 (57.5) | 451 (56.3) | |
| Race, N (%) | 0.012 | |||
| White | 5546 (70.4) | 412 (72.9) | 637 (79.5) | |
| Black | 1254 (15.9) | 83 (14.7) | 97 (12.1) | |
| Others | 1078 (13.7) | 70 (12.4) | 67 (8.4) | |
| Charlson–Romano comorbidity score, mean (SD) | 4.89 (3.77) | 5.16 (3.55) | 5.64 (3.79) | 0.02 |
| Diabetes | 3847 (48.8) | 280 (49.6) | 431 (53.8) | 0.12 |
| Hypertension | 7356 (93.4) | 524 (92.7) | 757 (94.5) | 0.18 |
| CVD | 1737 (22.1) | 112 (19.8) | 191 (23.9) | 0.08 |
| PVD | 2197 (27.9) | 148 (32.6) | 258 (32.2) | 0.89 |
Bold indicates statistically significant associations with a p-value of <0.05.
CVD, cerebrovascular disease; NE, number of episodes; PVD, peripheral vascular disease.